The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DexCom, Inc. (DXCM) ...

The Gross Law Firm Notifies Shareholders of DexCom, Inc.(DXCM) of a Class Action Lawsuit and an Upcoming Deadline ...

DexCom's key Q3 earnings factors include Stelo sales, updates on sales channels, and potential share buybacks. See why I ...

On Tuesday, DexCom Inc (DXCM) stock saw a decline, ending the day at $67.1 which represents a decrease of $-2.08 or -3.01% from the prior close of $69.18. The stock opened at $69 and touched a low of ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A ...

Investors and analysts reacted immediately to DexCom's revelation. The price of DexCom's common stock declined dramatically.

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that securities class action lawsuits have been filed ...

A top healthcare stock to own over the years has been DexCom (DXCM 1.18%). The company makes continuous glucose monitors ...

Valeo Financial Advisors LLC raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 31.8% in the third ...

Today, DexCom is the leading CGM company, with an estimated 40% market share. Importantly, CGM products are relatively nascent. DexCom generates nearly $4 billion in annual sales on a user base of ...

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Diabetes is a global epidemic, with more than 537 million people affected worldwide. DexCom (NASDAQ: DXCM) has improved patient lives with technology, and the stock has outperformed the stock ...